Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease

202214 citationsJournal Article

Authors

Arthur Kastl · Children's Hospital of Philadelphia

Kimberly N. Weaver · University of North Carolina at Chapel Hill

Xian Zhang · University of North Carolina at Chapel Hill

Jennifer A. Strople · Lurie Children's Hospital

Jeremy Adler · University of Michigan–Ann Arbor

Marla C. Dubinsky

Athos Bousvaros · Harvard University

Abstract

Humoral immune response to COVID-19 immunization in children with IBD was robust, despite a high proportion of this pediatric cohort being treated with immunosuppressive agents. Severe vaccine-related AEs were rare. Overall, these findings provide a high level of reassurance that pediatric patients with IBD respond well and safely to SARS-CoV-2 vaccination.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Viral gastroenteritis research and epidemiology Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The American Journal of Gastroenterology

Volume 118, Issue 1, pp. 129-137

DOI: 10.14309/ajg.0000000000002016

Field-Weighted Citation Impact: 1.40